Epidemiology
To date, two studies describe NDRG1-ERG fusion in a total of 3 prostate cancer cases with clinically localized disease (Pflueger et al., 2009; Esgueva et al., 2010) . Pflueger et al. and Esgueva et al. estimate NDGR1 to be the 5' fusion partner in up to 5% of ERG-rearranged prostate cancer. In direct comparison, TMPRSS2 is the 5' fusion partner in a majority (~78-82%) of ERGrearranged prostate cancer cases. SLC45A3 is the 5' partner to ERG in ~6-7% of rearrangement positive prostate cancer. Singular reports exist of a nonrecurring ERG fusion with HERPUD1 (Maher et al., 2009 ) and FKBP5 (Pflueger et al., 2011) , respectively. None of the well known prostate cancer cell lines (LNCaP, VCaP, 22Rv1, PC-3, NCI-H660 and DU145) harbor an NDRG1-ERG fusion (Pflueger et al., 2009) .
Genes involved and proteins

NDRG1
Location 8q24.22 Note NDRG1 (N-myc downstream regulated 1) is a multifunctional protein that is ubiquitously expressed in several tissues. It likely exerts its function cell type and tissue specific. It's described to act in stress response pathways, golgi transport, cell cycle regulation and mitosis. It is hypothesized that it has a tumor-suppressive function in epithelial cells since lower expression levels have been observed in adenocarcinoma compared to normal tissue. Defects in this gene are found in a subtype of the Charcot-Marie-Tooth disease type 4D (CMT4D), a peripheral neuropathy. 
Result of the chromosomal anomaly
Hybrid Gene
Transcript
The fusion breakpoint(s) on DNA level are unknown.
However, there are at least 2 distinct transcript isoforms described (Pflueger et al., 2009 ) (see figure above): FJ627786: NDRG1 (NM_006096) exon 3 joined with ERG (NM_004449) exon 6. FJ627787: NDRG1 (NM_006096) exon 2 joined with ERG (NM_004449) exon 6. The exon junctions of NDRG1-ERG isoforms are utilizing the same splice sites as the respective wildtype mRNAs possibly indicating the involvement of alternative splicing processes to produce distinct transcript isoforms.
Fusion Protein
Description Unlike TMPRSS2-ERG and SLC45A3-ERG, the NDRG1-ERG gene fusion transcripts are in frame, meaning that NDRG1 contributes 33 (FJ627786) and 21 (FJ627787) amino acids, respectively, to an NDRG1-ERG fusion protein (Pflueger et al., 2009 ). An antibody specific to NDRG1-ERG fusion protein does not exist yet. Hence, the expression of a fusion protein was indirectly verified by monitoring elevated ERG protein expression in cell lines that were transiently transfected with NDRG1-ERG expression vectors. In invasion assays, it was observed that 21)(q24; q22) in prostate cancer Pflueger D Atlas Genet Cytogenet Oncol Haematol. 2012; 16(8) confers increased invasiveness (unpublished results). Additional functions of the NDRG1-ERG fusion proteins have not been eluded further and it is unclear if they exert similar or differing functions compared to the N-terminally truncated ERG protein encoded by the TMPRSS2-ERG and SLC45A3-ERG fusions Klezovitch et al., 2008) .
